

# Financial Tear Sheet

## Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

## Stock Information

### PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$21.10</b>
Change (%)	<b>▼ 0.45 (2.09%)</b>
Volume	150,603
52 Week Low	\$9.80
Market Cap	\$579,944,514
Rolling EPS	-4.87
PE Ratio	N/A

Shares Outstanding 27,485,522

Data as of 05/22/17 12:45 p.m. ET



## Recent Paratek Pharmaceuticals News & Events

05/08/17 - 7:00 a.m.

Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July

There are currently no events scheduled.

05/04/17 - 7:01 a.m.

Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update

04/26/17 - 7:01 a.m.

Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide



## SEC Filings

Filing Date	Form
05/05/17	10-K/A
05/04/17	S-8
05/04/17	10-Q
04/24/17	8-K

## Management

Randy Brenner Senior Vice President -  
Regulatory, Quality and  
Technical Operations

Jason Burdette Vice President -  
Technical Operations

Jeanne Jew Senior Vice President -  
Business Development

Raj Padmanabhan Vice President -  
Information Technology

Regina Paglia Senior Vice President -  
Human Resources

Susan Perkins,  
J.D. Vice President -  
Intellectual Property

Evan Tzanis Senior Vice President -  
Clinical Development &  
Clinical Operations

Michael F. Bigham Chief Executive Officer  
and Chairman of the  
Board

Evan Loh, M.D.     President, Chief  
Operating Officer and  
Chief Medical Officer

William Haskel     General Counsel and  
Corporate Secretary

Douglas W. Pagán Chief Financial Officer

Adam Woodrow     Chief Commercial Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.